However, the current use of antibodies against VEGF for angiogenesis-associated disease treatment can cause numerous side effects, e.g., hypertension and proteinuria with bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody2–4. This evidence concerns the gene VEGFA and Hypertension.